Back HIV/AIDS HIV/AIDS Topics HIV Treatment

ICAAC Underway This Week in Denver

The 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) kicked off Tuesday and runs throughout the week in Denver. HIVandHepatitis.com will be on site to cover the latest research on HIV and hepatitis B and C.

alt

Read more:

U.S. Conference on AIDS Focuses on Epidemic in the South

The annual U.S. Conference on AIDS (USCA 2013), sponsored by the National Minority AIDS Council, took place this week in New Orleans, highlighting the burgeoning HIV epidemic in the southern states. Other themes included the Affordable Care Act, HIV prevention, aging, and fighting HIV stigma and criminalization.alt

Read more:

IAS 2013: Life Expectancy of HIV+ People in North America Increased by 15 Years

A 20-year-old HIV positive person on effective antiretroviral therapy (ART) in the U.S. or Canada has a remaining life expectancy of about 50 years, approaching that of HIV negative individuals, according to a poster presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last month in Kuala Lumpur.

alt

Read more:

Increased Risk of AIDS-defining Illnesses Seen Even at CD4 Counts of 500-750

HIV positive people with CD4 T-cell counts in the 500-749 cells/mm3 range still have a higher risk of AIDS-defining illnesses -- especially cancers -- compared to those with more than 1000 cells/mm3, although the risk is quite low, according to a study published in the August 6, 2013, advance edition of Clinical Infectious Diseases. These findings offer further evidence of the benefits of prompt antiretroviral treatment.

alt

Read more:

IAS 2013: Raltegravir/Etravirine Dual Regimen Maintains Viral Suppression

A regimen of raltegravir (Isentress) plus etravirine (Intelence) without NRTIs or protease inhibitors was able to keep HIV in check after switching from a standard regimen if patients did not have pre-existing NNRTI resistance, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

FDA Approves ViiV HIV Integrase Inhibitor Dolutegravir (Tivicay)

The U.S. Food and Drug Administration (FDA) today (August 12, 2013) approved the second HIV integrase inhibitor, dolutegravir, which will be marketed under the brand name Tivicay by ViiV Healthcare. Phase 3 studies showed that dolutegravir works as well as raltegravir (Isentress) or Atripla and is generally safe and well-tolerated.

alt

Read more:

IAS 2013: Single Tablet Regimens Do Not Always Produce Better HIV Treatment Outcomes

One pill per day does not necessarily lead to more durable HIV suppression than regimens containing more pills taken twice-daily, according to a study presented at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more: